TNBC, including basal-like and claudin-low subtypes, accounts for 10–20% of breast cancers and is characterized by a lack of PR, ER and HER2 overexpression.69 TNBC patients present with higher incidence of distant disease recurrence within 3 years of diagnosis, with a high frequency of visceral metastases.70 The prognosis for patients diagnosed with TNBC is poor, with patients who respond poorly to adjuvant treatment exhibiting worse outcomes.4 This evidence concerns the gene PGR and breast carcinoma.